MediLynx has partnered with the U.S. Cardiac Surgery Research Network (CTSN), government-funded National Heart, Lung and Blood Institute (NHLBI) and the National Institutes of Health (NIH), Medicalgorithmics said. MediLynx will be a provider of remote diagnostics solutions in a clinical trial conducted by renowned research centers.
The aim of the study is to determine the scale of the occurrence of postoperative atrial fibrillation in a selected group of patients.
“At MediLynx, we are proud to have been selected by the NHLBI / NIH-funded CTSN network to work with over 25 academic centers on this amazing study. (…), ”said William Moody, Chief Operating Officer (COO) of MediLynx.
“This is a very important reference project for us, confirming the highest class of PocketECG technology. Thanks to it, we will reach a wider group of potential customers with our solutions and we will increase the recognition of our technologies, which should support the development of sales on the US market. Cooperation with American academic centers is also an important signal for potential partners from other countries, additionally confirming the effectiveness of our technologies, “said Maciej Gamrot, CFO, member of the CFO Medicalgorithmics Management Board.
Medicalgorithmics is a high-tech company operating in the field of non-invasive medical devices, present on the market since 2005. The Group strives to become a leading provider of system and algorithmic solutions in cardiological diagnostics, in particular in the field of ECG signal analysis. The company operates in the USA and Asia, among others. In 2014, the company moved to the main market of the Warsaw Stock Exchange from NewConnect, where it has been listed since 2011.